September 20, 2021
FDA committee votes against COVID-19 vaccine boosters for general population
Editor's Note
The Food and Drug Administration’s (FDA’s) Vaccines and Related Biological Products Advisory Committee on September 17 voted that there was not enough safety and effectiveness data to approve a third Pfizer COVID-19 vaccine dose for those 16 years and older.
The committee did vote to recommend approval of a booster dose for people 65 years and older and those at high risk of severe COVID-19.
The committee also recommended approval of a booster for those with occupational risks, such as healthcare workers and teachers.
Free Daily News
- Study: Excessive nurse overtime, agency staffing harm patients
- Commentary: Technology no substitute for cadaver-based medical education
- Study: Early-stage breast cancer surgery may not be necessary after chemo, radiation
- Experimental brain implant translates thoughts to speech
- Nurses deem flexible, transparent scheduling key to satisfaction, retention
- OR Manager 2025 Career/Salary Survey offers opportunities to learn, give back
- The Joint Commission revises volume criteria for cardiac, stroke certifications
- Pulse oximetry monitoring at home found to save lives of high-risk opioid surgery patients
- New data suggest same-day discharge is safe for joint replacement patients with atrial fibrillation
- FBI investigates as Oracle health data breach exposes patient information
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement